Overview

A Study of LY3045697 After Multiple Oral Dosing in Healthy Participants

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and tolerability of LY3045697 after multiple doses and to determine how long LY3045697 remains in the body. Each participant is expected to complete 3 dosing periods. At least 7 days will pass between dosing periods.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Spironolactone